Page 35 - Read Online

Frame et al. Investigating models for prostate cancer research

30. Pellacani D, Packer RJ, Frame FM, Oldridge EE, Berry PA, 2016;17:1612-20.
Labarthe MC, Stower MJ, Simms MS, Collins AT, Maitland NJ. 37. Yang L, Taylor J, Eustace A, Irlam J, Denley H, Hoskin PJ, Alsner J,
Regulation of the stem cell marker CD133 is independent of promoter Buffa FM, Harris AL, Choudhury A, West CML. A gene signature for
hypermethylation in human epithelial differentiation and cancer. Mol selecting benefit from hypoxia modification of radiotherapy for high
Cancer 2011;10:94. risk bladder cancer patients. Clin Cancer Res 2017;23:4761-8.
31. Peitzsch C, Cojoc M, Hein L, Kurth I, Mabert K, Trautmann F, Klink 38. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, Berry
B, Schrock E, Wirth MP, Krause M, Stakhovsky EA, Telegeev GD, PA, Hyde CF, Lewis JL, Stower MJ, Maitland NJ, Collins AT. Gene
Novotny V, Toma M, Muders M, Baretton GB, Frame FM, Maitland expression profiling of human prostate cancer stem cells reveals a pro-
NJ, Baumann M, Dubrovska A. An epigenetic reprogramming inflammatory phenotype and the importance of extracellular matrix
strategy to resensitize radioresistant prostate cancer cells. Cancer Res interactions. Genome Biol 2008;9:R83.
2016;76:2637-51. 39. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M,
32. Adamson RE, Frazier AA, Evans H, Chambers KF, Schenk E, Essand Bhasin D, Chettiar S, Li C, Li PK, Maitland NJ, Collins AT. JAK-
M, Birnie R, Mitry RR, Dhawan A, Maitland NJ. In vitro primary cell STAT blockade inhibits tumor initiation and clonogenic recovery of
culture as a physiologically relevant method for preclinical testing of prostate cancer stem-like cells. Cancer Res 2013;73:5288-98.
human oncolytic adenovirus. Hum Gene Ther 2012;23:218-30. 40. Frame FM, Hager S, Pellacani D, Stower MJ, Walker HF, Burns JE,
33. Schenk E, Essand M, Kraaij R, Adamson R, Maitland NJ, Bangma Collins AT, Maitland NJ. Development and limitations of lentivirus
CH. Preclinical safety assessment of Ad[I/PPT-E1A], a novel vectors as tools for tracking differentiation in prostate epithelial cells.
oncolytic adenovirus for prostate cancer. Hum Gene Ther Clin Dev Exp Cell Res 2010;316:3161-71.
2014;25:7-15.
34. Schenk E, Essand M, Bangma CH, Consortium GF, Barber C, Behr 41. Swift SL, Burns JE, Maitland NJ. Altered expression of neurotensin
JP, Briggs S, Carlisle R, Cheng WS, Danielsson A, Dautzenberg IJ, receptors is associated with the differentiation state of prostate cancer.
Dzojic H, Erbacher P, Fisher K, Frazier A, Georgopoulos LJ, Hoeben Cancer Res 2010;70:347-56.
R, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Lindholm L, 42. Lang SH, Anderson E, Fordham R, Collins AT. Modeling the prostate
Magnusson M, Maitland N, Neuberg P, Nilsson B, Ogris M, Remy stem cell niche: an evaluation of stem cell survival and expansion in
JS, Scaife M, Schooten E, Seymour L, Totterman T, Uil TG, Ulbrich vitro. Stem Cells Dev 2010;19:537-46.
K, Veldhoven-Zweistra JL, de Vrij J, van Weerden W, Wagner E, 43. Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT,
Willemsen R. Clinical adenoviral gene therapy for prostate cancer. Morrone G, Culig Z, Maitland NJ, Erb HHH. The immunosuppressive
Hum Gene Ther 2010;21:807-13. cytokine interleukin-4 increases the clonogenic potential of prostate
35. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and stem-like cells by activation of STAT6 signalling. Oncogenesis
therapeutic effects of HDAC inhibitors. Cancer Lett 2009;280:125-33. 2017;6:e342.
36. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa 44. Oldridge EE, Walker HF, Stower MJ, Simms MS, Mann VM, Collins
M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, AT, Pellacani D, Maitland NJ. Retinoic acid represses invasion and
Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer stem cell phenotype by induction of the metastasis suppressors
EM, Den RB, Nguyen PL, Feng FY. Development and validation RARRES1 and LXN. Oncogenesis 2013;2:e45.
of a 24-gene predictor of response to postoperative radiotherapy 45. Rane JK, Pellacani D, Maitland NJ. Advanced prostate cancer -- a case
in prostate cancer: a matched, retrospective analysis. Lancet Oncol for adjuvant differentiation therapy. Nat Rev Urol 2012;9:595-602.

314 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 6, 2017